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Abstract
Botulinum neurotoxin serotype C (BoNT/C) is a neuroparalytic toxin associated with out-
breaks of animal botulism, particularly in birds, and is the only BoNT known to cleave two dif-
ferent SNARE proteins, SNAP-25 and syntaxin. BoNT/C was shown to be a good substitute
for BoNT/A1 in human dystonia therapy because of its long lasting effects and absence of
neuromuscular damage. Two triple mutants of BoNT/C, namely BoNT/C S51T/R52N/N53P
(BoNT/C α-51) and BoNT/C L200W/M221W/I226W (BoNT/C α-3W), were recently reported
to selectively cleave syntaxin and have been used here to evaluate the individual contribu-
tion of SNAP-25 and syntaxin cleavage to the effect of BoNT/C in vivo. Although BoNT/C α-
51 and BoNT/C α-3W toxins cleave syntaxin with similar efficiency, we unexpectedly found
also cleavage of SNAP-25, although to a lesser extent than wild type BoNT/C. Interestingly,
the BoNT/C mutants exhibit reduced lethality compared to wild type toxin, a result that corre-
lated with their residual activity against SNAP-25. In spite of this, a local injection of BoNT/C
α-51 persistently impairs neuromuscular junction activity. This is due to an initial phase in
which SNAP-25 cleavage causes a complete blockade of neurotransmission, and to a sec-
ond phase of incomplete impairment ascribable to syntaxin cleavage. Together, these
results indicate that neuroparalysis of BoNT/C at the neuromuscular junction is due to
SNAP-25 cleavage, while the proteolysis of syntaxin provides a substantial, but incomplete,
neuromuscular impairment. In light of this evidence, we discuss a possible clinical use of
BoNT/C α-51 as a botulinum neurotoxin endowed with a wide safety margin and a long last-
ing effect.
Author summary
The seven established Botulinum Neurotoxins serotypes (BoNT/A to G) and the many
BoNT subtypes, the causative agents of botulism, are the most poisonous substances
known (lethal doses in the low ng/kg range). Due to their toxicological properties, BoNTs
are Janus-faced toxins: potent pathogenic factors and potential bioterrorism agents as well
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as safe and efficacious therapeutics. BoNTs exert their neuroparalytic action by cleaving
SNARE proteins, either SNAP-25 or synaptobrevin/VAMP, which mediate neurotrans-
mitter release at the neuromuscular junction; BoNT/C is the only serotype shown to
cleave SNAP-25 and syntaxin-1 in vitro. Our study shows for the first time that this paral-
lel cleavage also occurs in vivo. By using mutated toxins reported to be syntaxin-selective,
we found that SNAP-25 proteolysis at the neuromuscular junction is the key determinant
of BoNT/C lethality as it completely blocks nerve-muscle transmission. Conversely, syn-
taxin-1 cleavage only attenuates nerve terminal activity without inactivating the synapse,
leading to only a partial decrease of neuromuscular functionality. As a result, the BoNT/C
mutants have dramatically reduced lethality, but still modulate neuromuscular junction
activity upon intramuscular injection. This aspect is particularly relevant considering the
possible use of syntaxin-specific BoNT/C derivatives to improve the present clinical utili-
zation of BoNTs.
Introduction
Few species of the bacterial genus Clostridium produce botulinum neurotoxins (BoNTs),
which cause the flaccid paralysis of botulism [1]. BoNTs are divided into at least seven dif-
ferent serotypes (BoNT/A to G) that comprise an increasing number of subtypes [1–3].
BoNTs are the most poisonous toxins known to date and display lethal doses in the low ng/
kg range [4, 5]. This remarkable potency is due to their selective action within the peripheral
nervous system, most notably at the neuromuscular junction (NMJ), where BoNTs inacti-
vate the machinery responsible for neurotransmitter release, causing muscle paralysis and
blockade of autonomic innervations [6]. Therefore, BoNTs are used to treat human diseases
characterized by hyperactivity of peripheral nerve terminals of both the motor and auto-
nomic nervous system [7]. This clinical use is almost exclusively restricted to BoNT/A1 as it
produces the longest effect, and in very few circumstances to BoNT/B1, mainly to overcome
BoNT/A1 resistance [5, 8].
The BoNT structure is composed of three domains that perform different functions [1]:
a) the C-terminal part harbors two binding sites for two different receptors that mediate
toxin anchoring and internalization within nerve terminals [9, 10]; b) an intermediate
domain responsible for the translocation of the catalytic domain into the cytosol of nerve
terminals [11, 12]; and c) the N-terminal catalytic domain, termed light chain (LC), which
is a metalloprotease cleaving one of the three SNARE (Soluble NSF Attachment Protein
Receptors) proteins, namely VAMP-1/2 (vesicle-associated membrane protein 1/2, also
known as synaptobrevin-1/2), SNAP-25 (synaptosomal-associated protein of 25 kDa) and
syntaxin-1A/1B (Stx) [13, 14]. These three proteins assemble into a complex, i.e. the SNARE
complex, which mediates the fusion of synaptic vesicles with the presynaptic membrane
[15], and their proteolysis is directly responsible for the pathogenicity of BoNTs [1, 6].
BoNT/B, /D, /F and /G cleave the vesicular SNARE protein VAMP-1/2 [16–19], whereas
BoNT/A, and /E cleave the plasma membrane protein SNAP-25 [20, 21]. BoNT/C is the
only toxin known to cleave two SNARE substrates, SNAP-25 and syntaxin-1A/1B, in vitro
[22–24]. Each toxin cleaves its SNARE at a unique site thereby removing different portions
of the respective substrates [13, 14]. Interestingly, while BoNTs cleaving VAMP cause a paral-
ysis of intermediate duration, the three serotypes that cleave SNAP-25 provide the shortest
and the longest persistence of action [25–28]: BoNT/E removes 26 amino acids from SNAP-
25 C-terminus and produces a muscle paralysis of a few days. BoNT/A and BoNT/C remove
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only nine and eight amino acids, respectively, and cause a paralysis that lasts for months in
humans [29–31]. However, it is currently unknown whether BoNT/C cleaves syntaxins at the
NMJ and to what extent this cleavage contributes to its long lasting paralysis.
Recently, two BoNT/C LC mutants were reported to display selective protease activity
against syntaxins [32]. These mutants offer the unique opportunity of dissecting the contribu-
tion of syntaxin and SNAP-25 cleavage to BoNT/C-induced paralysis and duration of action.
Therefore, we synthesized the respective full-length BoNT/C mutants and tested their potency
in vitro and in vivo. Surprisingly, we found that the two mutant toxins are much less toxic than
wild type BoNT/C and their respective toxicity correlates with an unexpected residual activity
against SNAP-25. Our findings suggest that BoNT/C lethality is mainly due to SNAP-25 cleav-
age, while the proteolysis of syntaxin accounts for a prolonged and substantial, albeit incom-
plete, impairment of neuromuscular transmission.
Results
BoNT/C mutants retain a residual activity on SNAP-25
Based on the work of Wang et al. (2011) [32], we produced the full-length triple mutants
BoNT/C S51T/R52N/N53P (hereafter referred to as BoNT/C α-51) and BoNT/C L200W/
M221W/I226W (BoNT/C α-3W) in Escherichia coli, along with wild type BoNT/C (BoNT/C-
wt). Amino acid substitutions are mapped in the crystal structure of BoNT/C-wt LC (PDB
2QN0) and shown in S1 Fig. Mutations are concentrated either in the S1’ pocket of the LC
(L200W/M221W/I226W, red spot), thus likely impinging on LC-substrate recognition around
the active site (blue spot), or on a region outside the active site (S51T/R52N/N53P, green spot),
which is possibly involved in LC-SNAREs interaction [32]. Recombinant toxins were exp-
ressed in E. coli, activated into di-chain toxins by host proteases, and one-step affinity-purified
using StrepTactin-sepharose matrix. The level of purification was suitable for biochemical and
toxicological characterization (S2 Fig).
We first tested the overall functionality of recombinant wild type and mutant BoNT/C in
cerebellar granular neurons (CGNs), which are highly sensitive to BoNTs and provide a rapid
and reliable method to assay the cleavage of SNARE proteins by western blot [28, 33]. We used
two specific antibodies that recognize both the intact and the truncated form of SNAP-25 and
syntaxin-1A/1B. After 12 hours of incubation, BoNT/C-wt cleaved both syntaxin-1A/1B (EC50
~ 0.25 nM) and SNAP-25 (EC50 ~ 0.05 nM), the latter more efficiently (Fig 1A). Importantly,
the extent of cleavage was similar to that of a “natural BoNT/C” purified from Clostridium bot-
ulinum, implying that production in E. coli provides BoNT/C-wt with identical biological
properties, as previously reported for other recombinant toxins [28, 34–36]. The two mutant
BoNT/C toxins cleaved syntaxin-1A/1B with similar efficiency (EC50 ~ 0.5 nM), which was
only slightly lower compared to BoNT/C-wt, indicating that the mutations do not alter the
mutant’s capacity to enter neurons. Contrary to what was reported in the original paper by
Wang et al. [32], we also detected cleavage of SNAP-25 (Fig 1A, middle and bottom panels),
with BoNT/C α-3W being more active (EC50 ~ 2.5 nM) than BoNT/C α-51 (EC50 > 5 nM)
indicating they are not specific for syntaxins. Notably, mutant BoNT/C toxins retained a
50-fold and>100-fold lower activity for SNAP-25 cleavage compared to BoNT/C-wt. This
unexpected result may be due to the different methods used, i.e. Wang et al. virally transduced
the gene encoding for mutant LCs while we exogenously added full-length toxins to the neu-
ron culture medium allowing uptake of physiological amounts. We also noticed that a certain
amount of syntaxin-1A/1B appears to be inaccessible to the three BoNT/Cs, even when toxins
were used at high concentrations. This became particularly evident when the incubation time
was extended to 24 hours (S3 Fig). Moreover, unlike BoNT/C-wt, the amount of SNAP-25
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cleaved by BoNT/C α-51 and BoNT/C α-3W did not increase significantly from 12 to 24 hours
(Fig 1A and S3 Fig middle and bottom panels).
To further characterize the enzymatic properties of the mutated toxins, we assayed the pro-
teolytic activity of their LCs in vitro against recombinant SNAP-25 and syntaxin1A. When
applied at equal concentrations, LC/C-wt, LC/C α-51 and LC/C α-3W cleaved syntaxin to a
similar extent (Fig 1B, upper panel), suggesting an overall similar enzymatic efficiency. On the
other hand, the activity of LC/C α-51 and LC/C α-3W against SNAP-25 (bottom panel) was
much lower (30-fold and 10-fold, respectively) than that of LC/C wt.
Collectively, these experiments demonstrate that mutant BoNT/C toxins are not specific for
syntaxin-1A/1B, but maintain a residual activity against SNAP-25 which is higher for BoNT/C
α-3W compared to BoNT/C α-51.
BoNT/C mutants have different neurodegenerative effects on neurons
To provide additional evidence on the proteolytic activity of BoNT/C mutants on SNAP-25,
we used an antibody that recognizes SNAP-25 segment 185–197, which corresponds to the
newly formed C-terminus generated upon cleavage by BoNT/A. This antibody recognizes
BoNT/A-cleaved, and not intact, SNAP-25 both in vitro and in vivo (S4 Fig) [27, 37, 38]. Since
BoNT/C cleaves SNAP-25 one amino acid downstream of the BoNT/A cleavage site [13, 31],
we asked whether this antiserum would also recognize BoNT/C-cleaved SNAP-25. The anti-
body recognized SNAP-25 cleaved by BoNT/C-wt as it caused an accumulation of staining like
that generated by BoNT/A1 (S4 Fig). Similar results were obtained upon treatment of CGNs
with BoNT/C mutants (12 hours, 5 nM) (Fig 2). In agreement with the western blot analysis,
Fig 1. BoNT/C triple mutants retain a residual activity against SNAP-25. (A) Proteolytic activity of BoNT/C
variants in cultured cerebellar granule neurons (CGNs). Full-length BoNT/C-wt or BoNT/C α-51 or BoNT/C α-
3W were added to cultured CGNs at indicated concentrations for 12 hours. The cleavage of syntaxin-1A/1B
and SNAP-25 was assayed in western blot by using two antibodies recognizing both the intact and the cleaved
forms of the proteins. (B) Recombinant syntaxin 1A fusion protein (1 μM, upper panel) or SNAP-25 (10 μM,
lower panel) spiked with the corresponding radiolabeled protein generated by in vitro transcription/translation in
the presence of [35S]-Met were incubated with various concentrations of LC/C-wt (cyan) or its mutants (α-51,
green; α-3W, red) in toxin assay buffer. After 1 h of incubation at 37˚C, samples were analyzed by SDS-PAGE.
Percentage of cleavage was quantified by means of the radiolabeled substrate by phosphorimaging. Data are
mean values of three to six independent experiments. Statistical significance was determined by a Student’s t-
test comparing the mean values between groups (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001, n.s. not
significant).
https://doi.org/10.1371/journal.ppat.1006567.g001
Molecular effects of BoNT/C substrate cleavage at NMJ
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006567 August 11, 2017 4 / 22
neurons treated with BoNT/C α-3W displayed a more prominent staining compared to those
neurons treated with BoNT/C α-51, yet less intense than that arising from BoNT/C-wt treat-
ment (12 hours, 0.5 nM). Moreover, prolonging the incubation time did not significantly
increase the amount of cleaved SNAP-25 (S5 Fig).
BoNT/C is long known to cause neurodegeneration in neuronal cultures [39–41], and this
effect can be monitored by staining neurofilament-200 (NF200), a major component of axon
cytoskeleton. After 12 hours of incubation, BoNT/C-wt caused a substantial loss of NF200 and
the formation of varicosities, also filled with cleaved SNAP-25, all along the neurites (Fig 2).
BoNT/C α-51 induced a very similar phenotype and caused an evident degeneration of neu-
rons. Intriguingly, neurons treated with BoNT/C α-3W neither displayed significant signs of
degeneration nor loss of NF200. This was even more clear after 24 hours of intoxication when
the detrimental effects of BoNT/C-wt and BoNT/C α-51 completely degenerated neurons (S5
Fig).
Together with the western blotting analyses, these results suggest that the three BoNT/C
variants have different neurodegenerative activity on CGNs and that this effect may not
depend on the proteolysis of SNAP-25 and syntaxin-1A/1B.
BoNT/C mutants are less toxic than wild type BoNT/C
Since the three toxins tested here have a similar activity against syntaxin-1A/1B and vary only
for the extent of SNAP-25 cleavage, we evaluated the contribution of SNAP-25 cleavage to
BoNT/C neuroparalysis. We first assessed the potency of the three toxins using the mouse
Fig 2. BoNT/C mutants display a different neurodegenerative effect on cultured neurons. CGNs were
treated with the indicated concentrations of BoNT/C-wt or mutants for 12 hours. Neurons were then fixed and
stained with an antibody against cleaved SNAP-25 (SNAP-25c, in red) and neurofilament-200 (NF200, in
green). Neurodegeneration was evaluated following the appearance of varicosities along neurites and the
loss of NF200 staining. Images are representative of at least three independent experiments. Scale bar,
10 μm.
https://doi.org/10.1371/journal.ppat.1006567.g002
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phrenic nerve hemidiaphragm (MPN) assay. This ex vivo assay mimics the respiratory failure
of botulism by intoxicating an explanted hemidiaphragm and allows for the recording of mus-
cle contraction capacity elicited by phrenic nerve stimulation [35, 42–45]. The addition of
BoNTs to the organ bath impairs nerve-muscle transmission and causes progressive muscle
neuroparalysis. The time needed to halve the initial twitch amplitude at a given concentration
(T50) is proportional to toxin potency [43] and can be used to provide very accurate compari-
sons of the activity of different BoNT preparations, including mutant toxins [35, 46]. The
black trace of Fig 3A shows the T50 values obtained for different bath concentrations of a stan-
dard BoNT/C, and provides a dose-response calibration curve (y = 148.95x-0.2089; R2 = 0.9806)
[45] which was used to compare the BoNT/C-wt and the two mutant toxins. BoNT/C-wt (100
pM; black diamond) displayed a potency similar to standard BoNT/C (Fig 3A), whereas to
achieve a T50 value within the calibration curve, BoNT/C α-3W (empty square) and BoNT/C
α-51 (filled square) were used at much larger concentrations (300 pM and 3000 pM, respec-
tively). Their potency was calculated as 12.1% and 3.4% of the BoNT/C-wt, respectively (Fig
3B). Hemidiaphragms were then stained for cleaved SNAP-25 (Fig 3C). Cleaved SNAP-25 was
detected in all muscles analyzed, suggesting that mutant toxins cleave SNAP-25 also at the
NMJ. At the same time, we detected minute levels in hemidiaphragms treated with a concen-
tration of BoNT/C α-51 (300 pM) which caused a very slow decline in muscle strength com-
pared to the higher concentration. These experiments suggest a strict correlation between the
potency of BoNT/C variants and their capacity to cleave SNAP-25.
We next assessed the potency of wild type and mutant BoNT/C toxins in vivo using the
mouse bioassay [47], in which mice are injected intraperitoneally with different amounts of
BoNTs and the dose causing death in the 50% of animals (i.e. 1 LD50) is used as a parameter
to estimate toxin lethality. BoNT/C-wt resulted in a LD50 = 0.75 ng/kg, whereas BoNT/C α-
3W and BoNT/C α-51 displayed LD50 = 150 ng/kg and LD50 = 750 ng/kg, respectively (Fig
4A and Table 1). Similarly to BoNT/C-wt, both mutants induced the classical symptoms of
botulism, i.e. the progressive collapse of flank musculature, ruffled fur, eye dryness, and
labored breath until respiratory failure. Relative to BoNT/C-wt lethality (Fig 4B, top panel),
botulism onset due to BoNT/C α-3W was very rapid as mice died very quickly (Fig 4B, mid-
dle panel). Conversely, BoNT/C α-51 induced botulism with a slower progression, with
lethality occurring significantly later (Fig 4B, bottom panel). Taken together, these observa-
tions suggest that the lethality/potency of the three toxins are linked to their capacity to
cleave SNAP-25.
Duration of neuroparalysis does not correlate with potency of mutant
BoNT/C toxins
A fundamental feature of BoNT/C is the long lasting paralysis induced following local injec-
tion in sub-lethal amounts. Among the toxins tested to date, BoNT/A1 and BoNT/C have the
longest persistence both in human and in mice [26, 48]. Accordingly, we tested the duration of
paralysis by mutant toxins upon injection in the hind limb with the Digit Abduction Score
(DAS) [49]. In this assay, animals are scored from 0 to 4, where 0 corresponds to normal
mobility and 4 to complete block of digit abduction. One LD50 of BoNT/C-wt induced a severe
paralysis within the first few days after administration, which was then progressively recovered
(Fig 5A). Surprisingly, one LD50 of BoNT/C α-3W induced a very quick onset followed by a
complete recovery within 48 hours. Even more surprisingly, one LD50 of BoNT/C α-51 had a
very long persistence, also exceeding that of BoNT/C-wt. Interestingly, we detected an acute
phase (days 1–5) of severe paralysis followed by a longer period of time characterized by a pro-
gressive, yet slow, recovery of function.
Molecular effects of BoNT/C substrate cleavage at NMJ
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To obtain a more quantitative time course of the paralyses, we measured the “evoked junc-
tion potential” (EJP). This electrophysiological analysis allows an accurate estimation of neuro-
transmitter release at the NMJ and can be used to monitor neurotransmission recovery in a
quantitative way [27]. Muscles treated with BoNT/C α-3W were fully paralyzed 24 hours after
injection, yet recovery was fast and nerve-muscle transmission reached control levels within
two weeks (Fig 5B). Unlike BoNT/C α-3W, BoNT/C-wt and BoNT/C α-51 completely abro-
gated neurotransmission for at least one week and recovery was slow, being incomplete even
after 5 weeks.
Altogether, these experiments indicate that the duration of the neuroparalytic effects of
BoNT/C mutants does not correlate with their respective potency.
Cleavage of SNAP-25 or syntaxin-1B have different functional
consequences on neuromuscular transmission
We hypothesized that lack of correlation between duration of paralysis and the relative
potency of BoNT/C variants was due to different cleavage of SNAP-25 and syntaxin. To test
this hypothesis, we stained soleus muscles of mice treated with wild type and mutant BoNT/C
toxins for cleaved SNAP-25. BoNT/C-wt induced long-lasting SNAP-25 cleavage, which was
reduced only at a later stage, when neurotransmission has significantly recovered (Fig 6A).
Fig 3. BoNT/C mutants display noticeable lower potency than wild type BoNT/C. (A) Activity of BoNT/C
variants at the MPN hemidiaphragm assay. The black trace represents a dose-response calibration curve
reporting the T50 value obtained at indicated bath concentration of a reference wild type BoNT/C [45].
Recombinant BoNT/C-wt (black diamond), tested at 100 pM displays a T50 comparable to the previous BoNT/
C-wt used at the same concentration. BoNT/C α-3W (white square) and BoNT/C α-51 (black square) need
much higher concentrations to achieve a T50 within the calibration curve. Error bars represent SD of n = 3–4
technical replicates. (B) Calculation of potency of BoNT/C mutants employing a power function fitted to the
dose-response calibration curve in A. (C) Immunofluorescent analysis of hemidiaphragms derived from MPN
assays. Hemidiaphragms treated with the indicated toxin and concentration were fixed immediately upon
completion of paralysis and stained for cleaved SNAP-25 (SNAP-25c, red). NMJs were spotted with α-
Bungarotoxin (α-BTX, in green). Images shown are representative of at least three independent experiments.
Scale bar, 10 μm.
https://doi.org/10.1371/journal.ppat.1006567.g003
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Two weeks after toxin treatment, we also observed NMJ fragmentation, extensive nerve termi-
nal sprouting, and synaptic remodeling, as previously reported [50]. Interestingly, cleaved
SNAP-25 was detected all along sprout membranes and within the presynaptic side of newly
formed nerve-muscle contacts. Following BoNT/C α-3W treatment, cleaved SNAP-25 was
clearly detectable 24 hours after injection, when neurotransmission is completely blocked, but
disappeared within four days, indicating that SNAP-25 1–198 has a half-life of<4 days (Fig
7A). NMJs displayed neither signs of postsynaptic remodeling nor nerve sprouting. These
results suggest that SNAP-25 cleavage is associated with a nerve terminal blockage and that
muscle paralysis persists as long as SNAP-25 is cleaved. On the other hand, Fig 8A shows that
in muscles treated with BoNT/C α-51, cleaved SNAP-25 is evident only at 24 hours after
Fig 4. BoNT/C mutants are poorly lethal in vivo. (A) Mouse bioassay for BoNT/C variants. CD1 female
mice weighting 20–24 grams were injected intraperitoneally with the indicated doses of BoNT/C-wt (cyan) or
BoNT/C α-51 (green) or BoNT/C α-3W (red). Survival after 96 hours is reported as the percentage of mice
survived with respect to the total group treated with the same amount of toxin. (B) Animals of the mouse
bioassay were monitored every 4 hours and their survival reported as a Kaplan-Meier plot. Top panel shows
BoNT/C-wt, middle panel is for BoNT/C α-3W and bottom panel is for BoNT/C α-51.
https://doi.org/10.1371/journal.ppat.1006567.g004
Table 1. Summary of the lethality of the different BoNT/C variants used in this study.
LD50 Lethal amount* Relative lethality
BoNT/C-wt 0.75 ng/kg 0.015 ng 1
BoNT/C α-3W 150 ng/kg 3 ng 1/200
BoNT/C α-51 750 ng/kg 15 ng 1/1000
A comparison of the lethal doses and the lethal amounts of BoNT/C-wt, BoNT/C α-3W and BoNT/C α-51, as
estimated from the mouse bioassay. The relative lethality of BoNT/C α-3W and BoNT/C α-51 with respect to
BoNT/C-wt is also shown.
(*) The lethal amount is calculated considering a mouse of 20 grams.
https://doi.org/10.1371/journal.ppat.1006567.t001
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injection and barely detectable at one and two weeks after. This indicates that SNAP-25 prote-
olysis occurs only at the very beginning of the time course and, consequently, the long lasting
neurotransmission impairment induced by BoNT/C α-51 cannot be ascribed to SNAP-25
cleavage. Therefore, we stained injected muscles for syntaxin-1A/1B. Control NMJs displayed
an intense and widespread staining characterized by large puncta of syntaxin-1B, the isoform
prevalently expressed at the NMJ [51] (Figs 6B, 7B and 8B). BoNT/C and mutant toxins caused
a large, though incomplete, loss of signal and the complete disappearance of syntaxin-1B clus-
ters. This effect, which we interpreted as syntaxin-1B cleavage, was prolonged for BoNT/C-wt
and it was not recovered even five weeks after injection (Fig 6B). In the case of BoNT/C α-3W,
loss of syntaxin-1B was obvious only 24 hours after toxin injection with return to control levels
between 7 to 14 days, indicating re-synthesis of syntaxin within 4 days and absence of LC/C α-
3W activity (Fig 7B). BoNT/C α-51 caused a loss of syntaxin-1B similar to BoNT/C-wt and
even 35 days post-injection there were no signs of recovery (Fig 8B). Importantly, nerve termi-
nals underwent remodeling with a time course and an intensity comparable to the BoNT/C-
wt-treated muscles, indicating a long-term impairment of NMJs. Considering that syntaxin re-
synthesis is rapid (Fig 7B), these results suggest that the long lasting effect of BoNT/C α-51 is
due to a persistent cleavage of syntaxin-1B and that LC/C α-3W activity has a very short half-
life in vivo. Moreover, it is interesting to note that syntaxin proteolysis by LC/C α-51 also
occurs in a phase in which SNAP-25 is not cleaved anymore (Fig 8B) which might be ascribed
to the>10-fold higher EC50 for SNAP-25 (EC50Stx 0.5 nM vs EC50SNAP-25 >5 nM).
Altogether, electrophysiological measurements and nerve terminal analyses indicate that
the cleavage of SNAP-25 is necessary for a complete neuromuscular block and muscle paraly-
sis, while the proteolysis of syntaxin-1B induces a significant, though incomplete, impairment
of neurotransmission.
Fig 5. Time course of neuroparalysis recovery upon a local injection of BoNT/C variants in the mouse
hind limb. (A) Digit Abduction Score (DAS) assay. 1 LD50 of BoNT/C-wt (cyan), or BoNT/C α-51 (green) or
BoNT/C α-3W (red) were injected intramuscularly in the mice hind limb and neuroparalysis was evaluated
according to [49]. The rescue from paralysis was monitored daily until complete recovery was attained. Traces
are representative of three independent experiments with at least 5 mice per condition. Error bars represent
SEM (B) Analysis of evoked post synaptic junction potentials (EJP) on injected soleus muscles. Mice were
treated as in A and at indicated time points soleus muscles were collected and processed for recordings of
EJPs, as previously reported [27]. Data are presented as a percentage of EJPs of control muscles. Each point
represents an average EJP amplitude obtained from at least 45 muscle fibers from three different mice per
condition. Statistical significance at each time point was determined by a Student’s t-test comparing the mean
values between either BoNT/C α-51 (green) or BoNT/C α-3W (red) compared to BoNT/C-wt (cyan) (* p<0.05,
** p<0.01, *** p<0.001, **** p<0.0001, n.s. not significant). Error bars represent SEM.
https://doi.org/10.1371/journal.ppat.1006567.g005
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A low dose of BoNT/C α-51 accounts for a prolonged modulation of
neurotransmission at the neuromuscular junction
Since the previous experiments showed that SNAP-25 cleavage occurs only with large amounts
of mutant toxins, we reasoned that a low dose might induce exclusive proteolysis of syntaxin-
1B. In this way, motor nerve activity should be attenuated without complete abrogation of neu-
rotransmission. To test this hypothesis, we opted to use BoNT/C α-51 because of its low activ-
ity against SNAP-25 and its long half-life. Toxin was injected in the hind-limb at a dose of 10
ng/kg, which corresponds to about 1/75 of its LD50 and 13-fold LD50 of BoNT/C-wt. Interest-
ingly, this “low dose” of BoNT/C α-51 did not result in a visible neuroparalysis (i.e., DAS score
0). Rather BoNT/C α-51 caused a substantial decrease of EJP amplitude in injected muscles,
which lasted for almost one month before returning to control levels (Fig 9A). Importantly, no
cleavage of SNAP-25 was detected during the entire time course (Fig 9B), while a significant
loss of syntaxin-1B staining occurred, especially within the first two weeks after injection (Fig
9C). Thereafter, syntaxin-1B expression recovered together with neurotransmission, suggest-
ing that nerve terminal activity (EJP amplitude) is proportional to the amount of syntaxin-1B.
In addition, we found a reduced atrophy of muscles injected with the low dose of BoNT/C α-
51 relative to muscles injected with either 1 LD50 of BoNT/C α-51 or 1 LD50 of BoNT/C-wt.
These results indicate that BoNT/C α-51 can persistently modulate nerve terminal activity
without compromising the overall activity of muscles.
Fig 6. Imaging of cleaved SNAP-25 and syntaxin-1 in muscles treated with BoNT/C-wt. Soleus muscles
of mice treated with BoNT/C-wt and used for the analysis of EJPs of Fig 5B were fixed immediately after the
electrophysiological recordings and stained for (A) cleaved SNAP-25 (SNAP-25c) or (B) Syntaxin-1A/1B (Stx-
1A/1B), both shown in red. NMJs were spotted with α-Bungarotoxin (α-BTX, in green). The first row of panels
represents the staining of a control muscle. Scale bar, 10 μm.
https://doi.org/10.1371/journal.ppat.1006567.g006
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Discussion
Among the many botulinum neurotoxins characterized so far, BoNT/C is unique in that it
cleaves two neuronal SNARE proteins, i.e. SNAP-25 and syntaxins. Although this parallel
activity was demonstrated over 20 years ago in cultured neurons [24], it has never been
reported at the NMJs nor was it clear which proteolytic event by BoNT/C causes neuroparaly-
sis. Our results show that BoNT/C cleaves both substrates at the NMJ, and that the key deter-
minant of potency and lethality is the proteolysis of SNAP-25 rather than syntaxin. We also
report that the cleavage of syntaxin-1B (syntaxin-1A is not expressed at the NMJ [51]) does
not cause complete block of the NMJ, although it accounts for a substantial impairment of
neurotransmission efficiency. Such a result is surprising considering the current view of the
SNARE-mediated mechanism of neuroexocytosis [52], but it is supported by previous reports
showing that: i) BoNT/C paralysis at NMJ can be reversed by 3,4-diaminopyridine [50], con-
sistent with a neuroparalytic effect lying on SNAP-25 cleavage rather than syntaxin, like for
BoNT/A1 [53]; ii) Syntaxin-1B knock out mice have a very limited life span, yet they survive
for a couple of weeks after birth, implying that neuromuscular transmission is viable [54, 55];
iii) Syntaxin-1B deficiency reduces but does not abolish NMJ capacity of neurotransmitter
release [55]. A likely explanation is the compensation of syntaxin-1B knock out/proteolysis at
the NMJ by other syntaxin isoforms. In knock out mice a minor expression of syntaxin-1A
was reported, which might occur as a compensatory mechanism [55]. In the present study, this
Fig 7. Imaging of cleaved SNAP-25 and syntaxin-1 in muscles treated with BoNT/C α-3W. Soleus
muscles of mice treated with BoNT/C α-3W and used for the analysis of EJPs of Fig 5B were fixed
immediately after the electrophysiological recordings and stained for (A) cleaved SNAP-25 (SNAP-25c) or (B)
Syntaxin-1A/1B (Stx-1A/1B), both shown in red. NMJs were spotted with α-Bungarotoxin (α-BTX, in green).
The first row of panels represents the staining of a control muscle. Scale bar, 10 μm.
https://doi.org/10.1371/journal.ppat.1006567.g007
Molecular effects of BoNT/C substrate cleavage at NMJ
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006567 August 11, 2017 11 / 22
possibility has to be discarded as syntaxin-1A would also be substrate of the toxins. On the
other hand, many non-cleavable syntaxins exist [5], raising the possibility that a cognate iso-
form compensates for syntaxin-1 biochemical knock down, leading to a largely inefficient, yet
functional neurotransmitter release.
As a general conclusion, syntaxin-1B proteolysis does not seem to be critical for the acute
neuroparalytic action of BoNT/C, which instead relies on SNAP-25 cleavage. Nonetheless, syn-
taxin cleavage may contribute to delaying the recovery process. In fact, fusion of synaptic vesi-
cles with the plasma membrane depends on the incorporation of multiple SNARE complexes
into SNARE super-complexes [56]. Since cleavage by BoNT/C occurs at the very C-terminus
and frees syntaxin from its transmembrane domain [5, 13, 14], it may be speculated that the
SNARE motif of cleaved-syntaxins are incorporated within SNARE super-complexes, and neg-
atively modulate vesicle fusion. This effect may be added to the long known effect of BoNT/C
(and BoNT/A) cleaved-SNAP-25 in modulating neuroexocytosis [5, 56].
We were surprised to find that BoNT/C mutants exert different neurodegenerative effects
in cultured neurons. This effect was previously attributed to cleavage of SNAP-25 and syn-
taxin-1A/1B, and to the complete elimination of one of them [40, 41]. However, we found that
in vitro neurodegeneration triggered by BoNT/C-wt and BoNT/C α-51 occurs even if a small
portion of syntaxin-1A/1B is resistant to cleavage. Moreover, BoNT/C α-3W is not cytotoxic
even if it displays proteolytic activity against SNAP-25 and syntaxin-1A/1B to an extent equal,
Fig 8. Imaging of cleaved SNAP-25 and syntaxin-1 in muscles treated with BoNT/C α-51. Soleus
muscles of mice treated with BoNT/C α-51 and used for the analysis of EJPs of Fig 5B were fixed immediately
after the electrophysiological recordings and stained for (A) cleaved SNAP-25 (SNAP-25c) or (B) Syntaxin-
1A/1B (Stx-1A/1B), both shown in red. NMJ were spotted with α-Bungarotoxin (α-BTX, in green). The first row
of panels represents the staining of a control muscle. Scale bar, 10 μm.
https://doi.org/10.1371/journal.ppat.1006567.g008
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if not superior, to BoNT/C α-51. These results indicate that SNARE cleavage may be not
directly implicated in BoNT/C-mediated neurodegeneration, at least in CGNs. An intriguing
alternative explanation may be the proteolysis of an additional substrate, still recognized by
BoNT/C-wt and BoNT/C α-51, but not by BoNT/C α-3W.
Fig 9. Time course of neurotransmission recovery in soleus muscles upon a local injection of a low
dose of BoNT/C α-51. (A) The black trace shows the analysis of evoked post synaptic junction potentials
(EJP) on soleus muscles injected intramuscularly with 10 ng/kg of BoNT/C α-51. At indicated time points
soleus muscles were collected and processed for the electrophysiological recordings of EJPs, as previously
reported [27]. Data are presented as a percentage of EJPs of control muscles. Each point represents an
average EJP amplitude obtained from at least 45 muscle fibers from three different mice per condition. Error
bars represent SEM. As a comparison, dotted trace shows the time course of EJP recovery obtained with 1
LD50 of BoNT/C α-51. Statistical significance at each time point was determined by a Student’s t-test
comparing the mean values (**** p<0.0001, n.s. not significant). Error bars represent SEM. (B and C)
Soleus muscles coming from the EJP analyses were fixed and stained for (B) cleaved SNAP-25 (SNAP-25c)
or (C) Syntaxin-1A/1B (Stx-1A/1B), both shown in red. NMJ were spotted with α-Bungarotoxin (α-BTX, in
green). The first row of panels represents the staining of a control muscle.
https://doi.org/10.1371/journal.ppat.1006567.g009
Molecular effects of BoNT/C substrate cleavage at NMJ
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006567 August 11, 2017 13 / 22
BoNT/C neurodegeneration does not occur at the NMJ in vivo in mice [50] and humans
[48, 57, 58]. A plausible explanation as to why neurodegeneration occurs only in cell culture
may be found in the different mode of entry of BoNT/C at the NMJ and in cultured neurons.
In vivo, like the other BoNTs, BoNT/C entry is restricted to unmyelinated areas of the nerve
terminals as axons are covered and protected by a tight nerve-blood-barrier. Neurons in cul-
ture are instead not myelinated and fully exposed to the action of all toxins residing in the cul-
ture medium. Accordingly, BoNT/C may affect neuronal compartments that are not accessible
in vivo. In any case, we show here that poisoned nerve terminals do not degenerate at any time
after toxin injection, a relevant finding considering that very high amounts of BoNT/C α-51
had been locally injected (1 LD50 15 ng/mouse). Rather, poisoned nerve terminals activate
and set in motion a profound remodeling of the NMJ as an attempt to bypass the functional
block of the synapse, similarly to what is observed upon BoNT/A1 and BoNT/B1 intoxication
[25, 27, 50, 59]. Therefore, our results suggest that the use of BoNT/C in humans would be
safe, and that BoNT/C α-51 may be a suitable candidate for this purpose. In fact, used at a dose
comparable to BoNT/C-wt, this toxin provides a persistent modulation of nerve terminal
activity without causing the complete paralysis of the muscle, a relevant finding for therapeutic
and cosmetic applications. BoNT/C α-51 would likely be ideal for applications characterized
by a narrow therapeutic window, when an optimal modulation of nerve terminal hyperactivity
is usually difficult to achieve without causing significant muscle weakening, as in focal dystonia
[5, 60]. Moreover, considering the low systemic toxicity in mice, this toxin may be suitable in
clinical conditions requiring considerable amounts of BoNT, like the treatment of large mus-
cles in post-stroke spasticity [5, 61, 62]. As for other BoNTs [29, 57, 58, 63], electrophysiologi-
cal testing on human volunteers can be used to assess the time course of action and the
susceptibility of human muscles to BoNT/C α-51 (or syntaxin-specific BoNTs). These prelimi-
nary analyses would reveal a dose-response window and may be essential in evaluating the
therapeutic potential of the toxin as well as its safety margin and immunogenicity [5].
In conclusion, this work highlights that minimal changes can functionally impact BoNT
biological activity, and suggests that inspection of structure-activity relationships may be used
to generate tailor-made toxins with ad hoc pharmacological properties to improve the present
applications and expand the clinical landscape of BoNT pharmacotherapy [41, 46, 64, 65].
Materials and methods
Reagents
Native BoNT/C and BoNT/A1 were purified as previously described [66, 67]. Cytosine β-D-
arabinofuranoside hydrochloride (C6645), DNAse I from bovine pancreas (DN25), poly-L-
lysine hydrobromide (P1274) and trypsin (T4799) were from Sigma Aldrich. μ-Conotoxin
GIIIB is from Alomone, Jerusalem, Israel. Primary antibodies: anti-SNAP-25 (SMI81,
ab24737) was from Abcam. Anti-SNAP-25 (cleaved) and syntaxin-1A/1B polyclonal antibod-
ies were produced in our laboratory and previously characterized [37, 68]. Secondary antibod-
ies conjugated to HRP were from Calbiochem; secondary antibodies for immunofluorescence
conjugated to Alexa Fluorophores 488 or 555 and α-Bungarotoxin conjugated to Alexa 647
were from Thermo Scientific, Waltham, MA, USA.
Production of recombinant BoNT/C and SNARE substrates
Full-length BoNT/C (GenBank: X53751.1) and BoNT/C LC (aa 1–430) as well as the mutants
thereof were produced, the former under biosafety level 2 containment (project number GAA
A/Z 40654/3/57), in E. coli strain M15pREP4 (Qiagen, Hilden, Germany) during 15 h of induc-
tion at 21˚C and purified on StrepTactin-sepharose matrix (IBA GmbH, Go¨ttingen, Germany)
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and Ni2+-nitrilotriacetic acid-agarose matrix (Qiagen), respectively, according to the manufac-
turers’ instructions. Aliquots of BoNT/C derivatives (in 100 mM Tris, pH 8.0) and of BoNT/C
LC derivatives (dialyzed against toxin assay buffer (150 mM potassium glutamate, 10 mM
HEPES-KOH, pH 7.2), were frozen in liquid nitrogen, and kept at -70˚C.
Recombinant substrate proteins, rat SNAP-25His6 [69] and a syntaxin fusion protein com-
prising an N-terminal His6-tag followed by the Halo-tag, rat syntaxin 1A aa 183–259, lucifer-
ase, and a C-terminal Strep-tag, were produced using the E. coli strains M15 pREP4 and
BL21-DE3 (Stratagene Europe, Ebsdorfergrund, Germany), respectively, purified via His6- or
His6- and Strep-tag, dialyzed against toxin assay buffer or PBS, pH 7.4, supplemented with 7%
(w/v) sucrose, and finally frozen in liquid nitrogen.
Radiolabeled substrates were generated by in vitro transcription/translation using the plas-
mids pSNAP-25his6 and pET29-HASyn(183–259)LS, the SP6/T7 coupled TNT reticulocyte
lysate system (Promega), and [35S]methionine (370 KBq/μL,>37 TBq/mmol, Hartmann Ana-
lytic, Braunschweig, Germany) according to the manufacturer´s instructions.
Concentrations of E. coli expressed proteins were determined subsequent to SDS-PAGE
and Coomassie blue staining by using a LAS-3000 imaging system (Fuji Photo Film), the
AIDA 3.51 program, and various known concentrations of BSA. The extent of hydrolytic acti-
vation of full-length BoNT/C by E. coli proteases was 81% (wild type), 73% (α-51), and 79%
(α-3W).
In vitro proteolytic activity
Cleavage assays were conducted using 10 μM SNAP-25 or 1 μM syntaxin fusion protein,
respectively, each 1 μL of transcription/translation mixture of the respective substrate as [35S]-
methionine-labeled protein, and purified LC/C derivative at 1 to 3 μM final concentrations in
10 μL. Incubation was done for 60 min at 37˚C in toxin assay buffer. Reactions were stopped
by the addition of an equal volume of double-concentrated sample buffer (120 mM Tris-HCl,
pH 6.75, 10% (v/v) β-mercaptoethanol, 4% (w/v) SDS, 20% (w/v) glycerol, 0.014% (w/v) brom-
phenol blue) and then subjected to SDS-PAGE using 10% or 15% tris/glycine gels (the latter
using acrylamide/bis-acrylamide in 73.5:1 ratio). Subsequently, gels were dried and radiola-
beled proteins were visualized employing a FLA-9000 phosphorimager (Fuji Photo Film, Co.,
Ltd., Tokyo, Japan). Quantification of cleavage was done by means of the radiolabeled sub-
strates by phosphorimaging using the Multigauge 3.2 software (Fuji Photo Film).
Neuronal cultures and intoxication assay
Primary cultures of rat cerebellar granule neurons (CGNs) were prepared from 6- to 8-day-old
rats as previously described [26]. Briefly, cerebella were isolated, mechanically disrupted and
trypsinized in the presence of DNase I. Cells were then collected and plated into 24 well plates
pre-coated with poly-L-lysine (50 μg/ml) at a cell density of 4x105 cells per well. Cultures were
maintained at 37˚C, 5% CO2, 95% humidity in BME (Basal Medium Eagle) supplemented
with 10% fetal bovine serum, 25 mM KCl, 2 mM glutamine and 50 μg/ml gentamicin (hereaf-
ter indicated as complete culture medium). To arrest growth of non-neuronal cells, cytosine
arabinoside (10 μM) was added to the complete culture medium 18–24 h after plating.
CGNs at 6–8 days in vitro (DIV) were incubated with increasing concentrations (from 0.01
nM to 5 nM) of the indicated BoNT/C in complete culture medium for 12 or 24 hours at 37˚C.
The specific proteolytic activity against SNAP-25 and syntaxin-1A/1B was evaluated via immu-
noblotting with antibodies that recognize both the intact and the truncated form of the two
proteins.
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Immunoblotting
Cells were directly lysed with Laemmli sample buffer containing protease inhibitors (Roche).
Cell lysates were loaded onto NuPage 12% Bis-Tris gels (Life technologies) and separated by
electrophoresis in MOPS buffer (Life technologies). Proteins were transferred onto Protran
nitrocellulose membranes (Whatman) and saturated for 1 h in PBS-T (PBS, 0.1% Tween 20)
supplemented with 5% non-fatty milk. Incubation with primary antibodies was performed
overnight at 4˚C. The membranes were then washed three times with PBS-T and incubated
with appropriate secondary antibodies for 1 h. Membranes were washed three times with PBS
and proteins revealed either with an Odyssey imaging system (LI-COR Bioscience) or with an
Uvitec gel doc system (Uvitec Cambridge).
Immunocytochemistry
CGNs were seeded onto 13 mm round glasses in 24-well plates at a cell density of 4x105 cells
per well. CGNs at 6–8 DIV were incubated for the indicated time and concentration of toxin
in complete culture medium at 37˚C. After treatment, neurons were fixed for 10 min with 4%
(w/v) paraformaldehyde in PBS and stained with an antibody against cleaved SNAP-25 and an
antibody against neurofilament-200 (NF200). Coverslips were mounted using Fluorescent
Mounting Medium (Dako) and examined with a Leica SP5 confocal microscope (Leica Micro-
systems, Wetzlar, Germany) equipped with 100X HCX PL APO NA 1.4 objective.
Mouse phrenic nerve (MPN) hemidiaphragm assay
The MPN assay was performed as described previously [43, 45]. To limit the consumption of
mice, the left and right phrenic nerve hemidiaphragms were excised from female mice of strain
RjHan:NMRI (18–25 g, Janvier, St Berthevin Cedex, France) and placed in an organ bath con-
taining 4 ml of Earle’s Balanced Salt Solution. The pH was adjusted to 7.4, and oxygen satura-
tion was achieved by gassing with 95% O2 and 5% CO2. The phrenic nerve was continuously
electro-stimulated at a frequency of 1 Hz with a pulse duration of 0.1 ms and a current of 25
mA to achieve maximal contraction amplitudes. Isometric contractions were recorded with a
force transducer (Scaime, Annemasse, France) and the software VitroDat (Fo¨hr Medical
Instruments GmbH (FMI), Seeheim, Germany). The resting tension of the hemidiaphragm
was approximately 10 mN. In each experiment, the preparation was first allowed to equilibrate
for 15 min under control conditions. Then, the buffer was exchanged to 4 ml of Earle’s Bal-
anced Salt Solution supplemented with 0.1% BSA and varying BoNT/C dilutions. The previ-
ously reported calibration curve determined for recombinant, E. coli host activated BoNT/C (y
(BoNT/C; 15, 50, 70, 100 and 233 pM) = 148.95x-0.2089; R2 = 0.9806) was used to calculate the
residual potency of BoNT/C mutants. The resulting paralytic half-times of BoNT/C mutants
were converted to the corresponding concentrations of wild type BoNT/C, using the equation
mentioned above. The toxicities were finally expressed relative to wild type BoNT/C.
Lethality assay
Swiss-Webster adult female CD1 mice (20–24 grams) were housed under controlled light/dark
conditions, and food and water were provided ad libitum. All experiments were performed in
accordance with the European Community Council Directive n˚ 2010/63/UE and approved
by the Italian Ministry of Health. LD50 were determined by injecting different doses of BoNT/
C-wt or BoNT/C α-3W or BoNT/C α-51 diluted in 0.9% NaCl 0.2% gelatin. Toxins were pre-
pared at a given concentration and mice were injected intraperitoneally with different volumes
Molecular effects of BoNT/C substrate cleavage at NMJ
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006567 August 11, 2017 16 / 22
according to their body weight in order to reach the indicated doses. Mice were monitored
every 4 hours for 96 hours, when the experiment was considered to be concluded.
Digit abduction score (DAS) assay
Swiss-Webster adult female CD1 mice weighing 20–24 g were injected in the left hind limb
with 1xLD50 of BoNT/C-wt (0.75ng/kg) or BoNT/C α-3W (150 ng/kg) or BoNT/C α-51 (750
ng/kg) diluted in 0.9% NaCl with 0.2% gelatin. Neuroparalysis was assessed daily according to
the Digit Abduction Score (DAS) assay scale, as previously reported [49].
Electrophysiological recordings of evoked junction potential
Mice were injected in the left hind limb as described for the DAS assay with indicated doses.
At scheduled times, mice were sacrificed by anesthetic overdose coupled to cervical dislocation
and the soleus muscle dissected. Electrophysiological recordings were performed in oxygen-
ated Krebs-Ringer solution, using intracellular glass microelectrodes (WPI) filled with 1 M
KCl and 2 M CH3COOK. Evoked junction potentials (EJP) were recorded in current-clamp
mode, starting from resting membrane potential of -70 mV, adjusted with direct current injec-
tion if needed. EJPs were elicited by supramaximal nerve stimulation at 0.5 Hz, using a suction
microelectrode connected to a S88 stimulator (Grass, Warwick, RI, USA). Muscle contraction
was prevented by 1 μM μ-Conotoxin GIIIB (Alomone, Jerusalem, Israel). Signals were ampli-
fied with intracellular bridge mode amplifier (BA-01X; NPI, Tamm, Germany), sampled using
a digital interface (NI PCI-6221; National Instruments, Austin, TX, USA) and recorded by
means of electrophysiological software (WinEDR; Strathclyde University, Glasgow, Scotland,
UK). EJPs measurements were carried out with Clampfit software (Molecular Devices, Sunny-
vale, CA, USA). EJPs represent the average value obtained analyzing at least three muscles (15
fibers/muscle) for each condition at each time-point and reported as a percentage with respect
to control muscles.
Imaging of neuromuscular junctions
Immediately after electrophysiological recording, soleus muscles were fixed in 4% paraformal-
dehyde in PBS for 10 min at RT. Each muscle was then separated in bundles of about 20–40
fibers to facilitate the following steps, in particular antibody penetration. In the case of
explanted and intoxicated hemidiaphragms, upon completion of paralysis, muscles were fixed
for 30 minutes. Samples were quenched in 50 mM NH4Cl in PBS and treated for 2 h with a
blocking solution (15% v/v goat serum, 2% w/v BSA, 0.25% w/v gelatin, 0.2% w/v glycine in
PBS, 0.5% Triton X-100) to saturate and permeabilize nerve terminals. Thereafter, incubation
with the following primary antibodies was carried out for at least 48 h in blocking solution
with either anti-cleaved SNAP-25 or anti-Syntaxin-1A/1B. Muscles were then extensively
washed and incubated with a secondary antibody conjugated with Alexa-555 diluted in block-
ing solution supplemented with α-Bungarotoxin conjugated to Alexa 647 to counterstain post-
synaptic nicotinic acetylcholine receptors. Images were collected with a Leica SP5 confocal
microscope (Leica Microsystems, Wetzlar, Germany) equipped with 100X HCX PL APO NA
1.4 objective. Laser excitation line, power intensity, and emission range were chosen according
to each fluorophore in different samples to minimize bleed-through.
Ethics statements
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14th March 2014) and with the guidelines established by the European Community Council
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(O.P.B.A.—Organismo Preposto al Benessere degli Animali) (protocol 359/2015).
Supporting information
S1 Fig. Mutations conferring to BoNT/C specificity for syntaxins. Space-filling representa-
tion of BoNT/C LC (PDB entry 2QN0) with highlighted triple mutations for syntaxin selectiv-
ity [32]: S51T/R52N/N53P (BoNT/C α-51) in green and L200W/M221W/I226W (BoNT/C
0078-3W) in red. Blue spot shows the metalloprotease active site.
(TIF)
S2 Fig. SDS-PAGE analysis of the different BoNT/C toxins used in the study. From left to
right, 250 nanograms of either native BoNT/C-wt, or recombinant BoNT/C-wt, BoNT/C α-51
or BoNT/C α-3W were loaded in a 12% gel under reducing conditions and revealed by Coo-
massie staining. The extent of hydrolytic activation of full-length BoNT/C by E. coli proteases
was 81% (wild type), 73% (α-51), and 79% (α-3W). The lower purity of α-51 does not compro-
mise its biological activity as deduced by the very similar EC50Stx of this toxin with respect to
BoNT/C α-3W and BoNT/C-wt in cultured neurons.
(TIF)
S3 Fig. The cleavage of SNAP-25 by BoNT/C mutants in CGNs does not increase by pro-
longing the incubation time to 24 hours. CGNs were treated as in Fig 1 but incubation was
prolonged to 24 hours. The cleavage of syntaxin-1A/1B and SNAP-25 was assayed by western
blot using two antibodies recognizing both the intact and the cleaved forms of the proteins.
(TIF)
S4 Fig. SNAP-25 cleaved by BoNT/C is recognized by an antibody raised against SNAP-25
cleaved by BoNT/A1. CGNs were treated with BoNT/A1 (0.1 nM) or BoNT/C-wt (0.1 nM) in
normal culture medium at 37˚C for 3 hours. Thereafter cells were fixed and stained with an
antibody raised against SNAP-25 segment 185–197 (red) [37], corresponding to the C-termi-
nus generated by BoNT/A1 cleavage (SNAP-25c). The antibody against neurofilament-200
(NF200, in green) is used as control staining. Scale bar, 10 μm.
(TIF)
S5 Fig. BoNT/C mutants display a different cytotoxic effect on cultured neurons. CGNs
were treated as in Fig 2 but incubation was prolonged to 24 hours. Neurons were then fixed
and stained with an antibody against cleaved SNAP-25 (SNAP-25c, in red) and neurofilament-
200 (NF200, in green). Cytotoxicity was evaluated following the appearance of varicosities
along neurites and the loss of NF200 staining. Images are representative of at least three inde-
pendent experiments. Scale bar, 10 μm.
(TIF)
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